ADMA Biologics (ADMA) Earnings Date & Reports

Key Takeaways

• ADMA Biologics is scheduled to report second quarter 2026 financial results on August 5, 2026, after the U.S. market closes, followed by a management conference call at 4:30 p.m. ET.
• Consensus estimates project Q2 2026 revenue of approximately $125 million to $126 million, representing modest year-over-year growth of roughly 3% compared to $121.98 million in Q2 2025.
• Earnings per share (EPS) consensus sits between $0.16 and $0.18, compared to $0.14–$0.15 reported in the same quarter last year.
• Investor focus will center on ASCENIV revenue trajectory and whether BIVIGAM stabilizes after a sharp 54% year-over-year decline in the first quarter.
• The stock has declined over 50% year-to-date, trading near $8.68 as of late July 2026, reflecting heightened investor caution following a significant Q1 revenue miss.
• Full-year 2026 company guidance calls for total revenue of $530 million to $560 million, with adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $265 million to $300 million.

Earnings Context and Why It Matters

ADMA Biologics enters its Q2 2026 earnings report at a pivotal moment. The company's stock has been under considerable pressure since its Q1 2026 release in May, when revenue of $114.49 million fell significantly short of consensus estimates near $140 million, triggering a sharp nearly 16% single-day selloff. The miss was driven primarily by a 54% drop in BIVIGAM sales, attributed to aggressive competitor discounting and distributor ordering disruptions in the standard immune globulin (IG) market. At the same time, ASCENIV — ADMA's higher-margin, differentiated IG product — posted 28% year-over-year growth, reaching $97.5 million in quarterly revenue. This Q2 report will test whether the ASCENIV growth engine can continue to carry the company while competitive pressures in the standard IG segment ease or persist.

Earnings Expectations

Wall Street analysts have set relatively tempered expectations for ADMA's second quarter. According to data aggregated from multiple research sources, the consensus revenue estimate for Q2 2026 falls in the range of $125.34 million to $126.16 million. This would represent a modest increase of approximately 3% from the $121.98 million reported in Q2 2025, and a roughly 10% sequential improvement from Q1 2026. On the bottom line, analyst consensus points to earnings per share between $0.16 and $0.18, compared to $0.14–$0.15 in the prior-year period. However, it is worth noting that full-year 2026 consensus revenue estimates of roughly $535 million sit comfortably within the company's own guidance range of $530 million to $560 million, suggesting the broader analyst community views the Q1 shortfall as partially transitory. Key metrics beyond the headline numbers will include ASCENIV revenue growth, BIVIGAM sales stabilization, gross margin trends (which reached 71% in Q1), and any updates to the company's operating expense outlook as it invests in pipeline programs including SG-001, its preclinical hyperimmune globulin candidate targeting S. pneumoniae.

AI Screener

For investors seeking to identify opportunities beyond individual earnings reports, Tickeron's AI Screener offers a powerful AI-driven stock and ETF discovery platform. The tool enables traders and investors to filter thousands of securities based on customizable criteria, including technical patterns, fundamental health, volatility profiles, industry classification, market capitalization, and proprietary AI-generated signals. Whether scanning for breakout candidates, trending sectors, or stocks exhibiting specific chart patterns, the AI Screener streamlines the research process by surfacing relevant trade ideas far more efficiently than manual screening methods. Users can tailor their searches to match specific investing styles and time horizons, making it a versatile resource for both active traders and longer-term investors navigating earnings season and beyond.

Market Reaction and Investor Sentiment

Investor sentiment heading into the Q2 2026 report remains cautious. ADMA shares have declined more than 50% year-to-date, falling from $18.24 at the start of 2026 to approximately $8.68 as of late July. The stock currently trades near the lower end of its 52-week range of $7.21 to $20.46. The Q1 2026 earnings miss and the associated 15.97% single-day decline remain fresh in investors' minds, and the company's decision to withdraw longer-term guidance while maintaining only a full-year 2026 outlook has added to uncertainty. Despite the depressed share price, Wall Street analyst ratings remain predominantly positive, with a consensus "Moderate Buy" or "Buy" rating and average price targets ranging from $17 to $19.67 — implying potential upside of more than 95% from current levels. Analyst firms including Mizuho (Outperform, $17 target) and Canaccord Genuity (Buy, $18 target) have maintained constructive views. However, the wide gap between analyst targets and the current stock price itself reflects market skepticism that will need to be addressed by concrete signs of BIVIGAM stabilization and sustained ASCENIV momentum in the Q2 print and management commentary.

Forward Outlook and Key Factors to Monitor

Looking beyond the Q2 2026 release, several factors will shape the investment narrative for ADMA Biologics in the second half of the year. First and foremost, the trajectory of ASCENIV remains the cornerstone of the company's growth story. The product's recent pediatric label expansion by the U.S. Food and Drug Administration (FDA) represents a meaningful catalyst that could broaden the addressable patient population and drive further prescriber adoption. Management noted in Q1 that April 2026 direct sales run rates were tracking in line with first-quarter levels, providing an early indication of continued demand.

On the competitive front, the standard IG market — where BIVIGAM competes — has seen new entrants applying aggressive pricing strategies that eroded average selling prices by an estimated 15% to 20% in Q1. Any signs that this pricing pressure is moderating, or that ADMA's distribution channels are normalizing inventory levels, would be received positively. Elevated days sales outstanding (DSO), which reached approximately 107 days in Q1 (above the company's target of 90–105 days), will also be a metric worth monitoring as an indicator of working capital efficiency.

Additionally, investors should watch for pipeline updates on SG-001, ADMA's preclinical hyperimmune globulin candidate. The company has indicated plans to file a Pre-Investigational New Drug (Pre-IND) application this year and estimates a potential peak market opportunity of $300 million to $500 million. Finally, ADMA's strong balance sheet — with approximately $138 million in cash, pro forma net leverage below 0.5x, and roughly $100 million in available borrowing capacity — provides financial flexibility to navigate near-term headwinds while investing in long-term growth initiatives. How management frames the balance of 2026 during the conference call will likely carry as much weight as the reported numbers themselves.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations